Matrix metalloproteinases as emerging targets in anticancer therapy: Status and prospects

Expert Opinion on Therapeutic Targets

Volumn 4, Issue 5, 2000, Pages 609-633

  Sternlicht, Mark D ^a   Bergers, Gabriele ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

angiogenesis; cancer; clinical trials; matrix metalloproteinase inhibitors; matrix metalloproteinases; preclinical trials

Indexed keywords

EID: 0000546937     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.4.5.609     Document Type: Review

References (193)

1. STERNLICHT MD, WERB Z: ECM proteinases. In: Guidebook to the Extracellular Matrix, Anchor and Adhesion Proteins. Kreis T, Vale R (Eds.), Oxford University Press, Oxford, UK (1999):503-562.
2. BERGERS G, COUSSENS LM: Extrinsic regulators of epithelial tumor progression: metalloproteinases. Curr Opin. Genet. Dev. (2000) 10 (1):120-127.
3. WERB Z: ECM and cell surface proteolysis: regulating cellular ecology. Cell (1997) 91 (4):439-442.
4. GIAMBERNARDI TA, GRANT GM, TAYLOR GP et al: Overview of matrix metalloproteinase expression in cultured human cells. MatrixBiol. (1998) 16 (8):483-496.
5. COUSSENS LM, WERB Z: Matrix metalloproteinases and the development of cancer. Chem. Biol. (1996) 3(11):895-904.
6. MCKERROW JH, BHARGAVA V, HANSELL E et al.: A functional proteomics screen of proteases in colorectal carcinoma. Mol. Med. (2000) 6 (5):450-460.
7. BERGERS G, JAVAHERIAN K, LO KM, FOLKMAN J, HANAHAN D: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (1999) 284 (5415):808-812.
8. STERNLICHT MD, LOCHTER A, SYMPSON CJ et al: The stromal proteinase MMP-3/stromelysin-1 promotes mammary carcinogenesis. Cell (1999) 98(2):137-146.
9. STERNLICHT MD, BISSELL MJ, WERB Z: The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene (2000) 19 (8):1102-1113.
10. MASSON R, LEFEBVRE O, NOËL A et al: In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J. Cell Biol. (1998) 140(6):1535-1541.
11. WILSON CL, HEPPNER KJ, LABOSKY PA, HOGAN BL, MATRISIAN LM: Intestinal tumorigenesis is suppressed in mice lackingthe metalloproteinase matrilysin. Proc Natl. Acad. Sci. USA (1997) 94(4):1402-1407.
12. RUDOLPH-OWEN LA, CHAN R, MULLER WJ, MATRISIAN LM: The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res. (1998) 58 (23):5500-5506.
13. D'ARMIENTO J, DICOLANDREA T, DALAL SS et al.: Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis. Mol Cell. Biol. (1995) 15(10):5732-5739.
14. MARTIN DC, RÜTHER U, SANCHEZ-SWEATMAN OH, ORR FW, KHOKHA R: Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. Oncogene (1996) 13 (3):569-576.
15. MARTIN DC, SANCHEZ-SWEATMAN OH, HO AT et al: Transgenic TIMP-1 inhibits simian virus 40 T antigen-induced hepatocarcinogenesis by impairment of hepatocellular proliferation and tumor angiogenesis. Lab. Invest. (1999) 79 (2):225-234.
16. LOCHTER A, GALOSY S, MUSCHLER J et al.: Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell Biol (1997) 139 (7):1861-1872.
17. STÖCKER W, GRAMS F, BAUMANN U et al.: The metzincins-topological and sequential relations between the astacins, adamalysins, serralysins and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Science (1995) 4(5):823-840.
18. BLACK RA, WHITE JM: ADAMs: focus on the protease domain. Curr. Opin. Cell Biol. (1998) 10(5):654-659.
19. TANG BL, HONG W: ADAMTS: a novel family of proteases with an ADAM protease domain and thrombospondin 1 repeats. FEBS Lett. (1999) 445 (2-3):223-225.
20. IRUELA-ARISPE ML, VAZQUEZ F, ORTEGA MA: Antiangio-genic domains shared by thrombospondins and metallospondins, a new family of angiogenic inhibitors. Ann. NY Acad. Sci. (1999) 886:58-66.
21. BEIN K, SIMONS M: Thrombospondin Type 1 repeats interact with matrix metalloproteinase 2: regulation of metalloproteinase activity. J. Biol. Chem. (2000) (In Press).
22. NAGASE H, WOESSNER JF: Matrix metalloproteinases. J. Biol. Chem. (1999) 274 (31):21491-21494.
23. LLANO E, PENDAS AM, FREIJE JP etal: Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overex-pressed in brain tumors. Cancer Res. (1999) 59(11):2570-2576.
24. VALESCO G, PENDAS AM, FUEYO A et al: Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J. Biol. Chem. (1999) 274(8):4570-4576.
25. PARK HI, NI J, GERKEMA FE et al.: Identification and characterization of human endometase (matrix metalloproteinase-26) from endometrial tumor. J. Biol Chem. (2000) 275 (27):20540-20544.
26. STERNLICHT MD, COUSSENS LM, VU TH, WERB Z: Biology and regulation of the matrix metalloproteinases. In: Matrix Metalloproteinase Inhibitors in Cancer Therapy. Clendeninn NJ, Appelt K (Eds.), Humana Press, Totowa, New Jersey, USA (2000):1-37.
27. GURURAJAN R, GRENET J, LAHTI JM, KIDD VJ: Isolation and characterization of two novel metalloproteinase genes linked to the CdC2L locus on human chromosome 1p36.3. Genomics (1998) 52:101-106.
28. VAN WART HE, BIRKEDAL-HANSEN H: The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. USA (1990) 87 (14):5578-5582.
29. PEI D, WEISS SJ: Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature (1995) 375 (6528):244-247.
30. STRONGIN AY, COLLIER I, BANNIKOV G et al.: Mechanism of cell surface activation of 72-kDaType IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. (1995) 270 (10):5331-5338.
31. ZUCKER S, DREWS M, CONNER C et al: Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane Type 1-matrix metalloproteinase 1 (MT1-MMP).J. Biol. Chem. (1998) 273 (2):1216-1222.
32. OKUMURA Y, SATO H, SEIKI M, KIDO H: Proteolytic activation of the precursor of membrane Type 1 matrix metalloproteinase by human plasmin. A possible cell surface activator. FEBS Lett. (1997) 402 (2-3):181-184.
33. BROOKS PC, STRÖMBLAD S, SANDERS LC etal: Localiza tion of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell (1996) 85(5):683-693.
34. YU Q, STAMENKOVIC I: Localization of matrix metallo proteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. (1999) 13 (1):35-48.
35. MORINI M, MOTTOLESE M, FERRARI N et al.: The alpha3beta1 integrin is associated with mammary carcinoma cell metastasis, invasion and gelatinase B (mmp-9) activity. Int.J. Cancer (2000) 87 (3):336-342.
36. TOTH M, SADO Y, NINOMIYA Y, FRIDMAN R: Biosynthesis of alpha2(IV) and alpha1(IV) chains of collagen IVand interactions with matrix metalloproteinase-9. J. Cell. Physiol. (1999) 180 (1):131-139.
37. LUKASHEV ME, WERB Z: ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol (1998) 8:437-441.
38. LIU Z, ZHOU X, SHAPIRO SD et al.: The serpin, (X1-proteinase inhibitor, is a critical substrate for gelatinase B/MMP-9 in vivo. Cell (2000) 102 (In Press).
39. SUZUKI M, RAAB G, MOSES MA, FERNANDEZ CA, KLAGSBRUN M: Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J. Biol. Chem. (1997) 272 (50):31730-31737.
40. PATTERSON BC, SANG QXA: Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IVcollagenase (MMP-9).J. Biol. Chem. (1997) 272(46):28823-28825.
41. LEVI E, FRIDMAN R, MIAO HQ et al.: Matrix metallopro-teinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc. Natl. Acad. Sci. USA (1996) 93 (14):7069-7074.
42. FOWLKES JL, ENGHILD JJ, SUZUKI K, NAGASE H: Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J. Biol. Chem. (1994) 269 (41):25742-25746.
43. THOMASSET N, LOCHTER A, SYMPSON CJ et al: Expres sion of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development. Am. J. Pathol. (1998) 153 (2):457-467.
44. TLSTY TD: Cell-adhesion-dependent influences on genomic instability and carcinogenesis. Curr. Opin. Cell Biol. (1998) 10 (5):647-653.
45. KATAOKA H, UCHINO H, IWAMURA T et al.: Enhanced tumor growth and invasiveness in vivoby a carboxyl-terminal fragment of a-proteinase inhibitor generated by matrix metalloproteinases: a possible modulatory role in natural killer cytotoxicity. Am. J. Pathol. (1999) 154 (2):457-468.
46. MCQUIBBAN GA, GONG JH, TAMEM etal: Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science (2000) 289 (5482):1202-1206.
47. ALEXANDER CM, HOWARD EW, BISSELL MJ, WERB Z: Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene. J. Cell Biol. (1996) 135(6 Pt 1):1669-1677.
48. POWELL WC, FINGLETON B, WILSON CL, BOOTHBY M, MATRISIAN LM: The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr. Biol. (1999) 9 (24):1441-1447.
49. ARENAS-HUERTERO FJ, HERRERA-GOEPFERT R, DELGADO-CHAVEZ R et al: Matrix metalloproteinases expressed in squamous cell carcinoma of the oral cavity: correlation with clinicopathologic features and neo-adjuvant chemotherapy response. J. Exp. Clin. Cancer Res. (1999) 18 (3):279-284.
50. DU B, WANG P, GUO X: Expression of membrane Type 1-matrix metalloproteinase in laryngeal carcinoma. Pathol. Oncol. Res. (1999) 5(3):214-217.
51. OBERG A, HOYHTYA M, TAVELIN B, STENLING R, LINDMARK G: Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloprote-inases (TIMP-1, TIMP-2) in colorectal cancer. AntiCancer Res. (2000) 20(2B):1085-1091.
52. HANEMAAIJER R, VERHEIJEN JH, MAGUIRE TM et al.: Increased gelatinase-A and gelatinase-B activities in malignantvs.benignbreast tumors. Int. J. Cancer (2000) 86(2):204-207.
53. NAKANISHI K, KAWAI T, SATO H et al.: Expression of matrix metalloproteinase-2 (MMP-2) and of membrane-type-1-matrix metalloproteinase (MT1-MMP)intransitional cell carcinomaofthe upper urinary tract. Hum. Pathol. (2000) 31(2):193-200.
54. ARA T, FUKUZAWA M, KUSAFUKA T et al.: Immunohisto-chemical expression of MMP-2, MMP-9 and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome. J. Pediatr. Surg. (1998) 33(8):1272-1278.
55. BANDO E, YONEMURA Y,ENDOU Yet al.: Immunohisto-chemical study of MT-MMP tissue status in gastric carcinoma and correlation with survival analyzed by univariate and multivariate analysis. Oncol. Rep. (1998) 5(6):1483-1488.
56. ETOH T, INOUE H, YOSHIKAWA Y et al.: Increased expression of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to cancer aggressiveness. Gut (2000) 47(1):50-56.
57. ITO T, ITO M, SHIOZAWA J et al.: Expression of the MMP-1 in human pancreatic carcinoma: relationship with prognostic factor. Mod. Pathol. (1999) 12(7):669-674.
58. MAATTA M, SOINI Y, LIAKKA A, AUTIO-HARMAINEN H: Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and membrane Type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin. Cancer Res. (2000) 6(7):2726-2734.
59. MOSER PL, KIEBACK DG, HEFLER L et al.: Immunohisto-chemical detection of matrix metalloproteinases (MMP) 1 and 2 and tissue inhibitor of metalloprote-inase 2 (TIMP 2) in stage IB cervical cancer. AntiCancer Res. (1999) 19(5C):4391-4393.
60. TALVENSAARI-MATTILA A, PAAKKO P, TURPEENNIEMI-HUJANEN T: MMP-2 positivity and age less than 40 years increases the risk for recurrence in premeno-pausal patients with node-positive breast carcinoma. Breast Cancer Res. Treat. (1999) 58(3):287-293.
61. VAISANEN A, KALLIOINEN M, TASKINEN PJ, TURPEENNIEMI-HUJANEN T: Prognostic value of MMP-2 immunoreactive protein (72 kD Type IV collagenase) in primary skin melanoma. J. Pathol. (1998) 186(1):51-58.
62. YAMASHITA K, MORI M, SHIRAISHI T, SHIBUTA K, SUGIMACHI K: Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin. Cancer Res. (2000) 6(3):1169-1174.
63. ARA T, KUSAFUKA T, INOUE M et al.: Determination of imbalance between MMP-2 and TIMP-2 in human neuroblastoma by reverse-transcription polymerase chain reaction and its correlation with tumor progression. J. Pediatr. Surg. (2000) 35(3):432-437.
64. GOHJI K, FUJIMOTO N, OHKAWA J, FUJIIA, NAKAJIMA M: Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor ofrecurrence ofurothe-lial cancer. Br. J. Cancer (1998) 77(4):650-655.
65. CAENAZZO C, ONISTO M, SARTOR L et al.: Augmented membrane Type 1 matrix metalloproteinase (MT1-MMP):MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis. Clin. Cancer Res. (1998) 4(9):2179-2186.
66. SAKAKIBARA M, KOIZUMI S, SAIKAWA Y et al.: Membrane-type matrix metalloproteinase-1 expression and activation of gelatinase A as prognostic markers in advanced pediatric neuroblastoma. Cancer (1999) 85(1):231-239.
67. KUITTINEN O, SAVOLAINEN ER, KOISTINEN P, TURPEENNIEMI-HUJANEN T: Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML. AntiCancer Res. (1999) 19(5C):4395-4400.
68. KANAYAMA H, YOKOTA K, KUROKAWA Y et al.: Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer (1998) 82(7):1359-1366.
69. TALVENSAARI A, APAJA-SARKKINEN M, HOYHTYA M et al.: Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferen-tiation. Gynecol. Oncol. (1999) 72(3):306-311.
70. CHENARD MP, O'SIORAIN L, SHERING Set al.: High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int. J. Cancer (1996) 69(6):448-451.
71. AHMAD A, HANBY A, DUBLIN E et al.: Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression. Am. J. Pathol. (1998) 152(3):721-728.
72. DAVIDSON B, GOLDBERG I, KOPOLOVIC J et al.: MMP-2 and TIMP-2 expression correlates withpoor prognosis in cervical carcinoma-a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol. Oncol. (1999) 73(3):372-382.
73. NUOVO GJ, MACCONNELL PB, SIMSIR A, VALEA F, FRENCH DL: Correlation of the in situ detection of polymerase chain reaction-amplified metalloprote-inase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res. (1995) 55(2):267-275.
74. SCULLY SP, BEREND KR,QI WN, HARRELSON JM: Collage- nasespecificityinchondrosarcoma metastasis. Braz. J. Med. Biol. Res. (1999) 32(7):885-889.
75. MURRAY GI, DUNCAN ME, O'NEIL P, MELVIN WT, FOTHERGILL JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nature Med. (1996) 2(4):461-462.
76. ZENG ZS, HUANG Y, COHEN AM, GUILLEM JG: Predic-tionof colorectal cancer relapse and survivalviatissue RNA levels of matrix metalloproteinase-9. J. Clin. Oncol. (1996) 14(12):3133-3140.
77. SUNAMI E, TSUNO N, OSADA T et al.: MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist (2000) 5(2):108-114.
78. MURRAY GI, DUNCAN ME, O'NEIL P et al.: Matrix metalloproteinase-1is associated with poor prognosis in oesophageal cancer. J. Pathol. (1998) 185(3):256-261.
79. INOUE T, YASHIRO M, NISHIMURA S et al.: Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int. J. Mol. Med. (1999) 4(1):73-77.
80. ALLGAYER H, BABIC R, BEYER BC et al.: Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer. Oncology (1998) 55(2):152-160.
81. MORI M, MIMORI K, SHIRAISHI T et al.: Analysis of MT1-MMP and MMP2 expression in human gastric cancers. Int. J. Cancer (1997) 74(3):316-321.
82. GRIGIONI WF, D'ERRICO A, FORTUNATO C et al.: Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. Mod. Pathol. (1994) 7(2):220-225.
83. MICHAEL M, BABIC B, KHOKHA R et al.: Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J. Clin. Oncol. (1999) 17(6):1802-1808.
84. HERBST RS, YANO S, KUNIYASU H et al.: Differential expression of E-cadherin and Type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin. Cancer Res. (2000) 6(3):790-797.
85. YLISIRNIO S, HOYHTYA M, TURPEENNIEMI-HUJANEN T: Serum matrix metalloproteinases-2,-9 and tissue inhibitors of metalloproteinases-1,-2 in lung cancer-TIMP-1 as a prognostic marker. AntiCancer Res. (2000) 20(2B):1311-1316.
86. KODATE M, KASAI T,HASHIMOTO Het al.: Expression of matrix metalloproteinase (gelatinase) in T1 adenocar-cinoma of the lung. Pathol. Int. (1997) 47(7):461-469.
87. VAISANEN A, KALLIOINEN M, VON DICKHOFF K et al.: Matrix metalloproteinase-2 (MMP-2) immunoreactive protein-a new prognostic marker in uveal melanoma? J. Pathol. (1999) 188(1):56-62.
88. MIYAJIMA Y, NAKANO R, MORIMATSU M: Analysis of expression of matrix metalloproteinases-2 and-9 in hypopharyngeal squamous cell carcinoma by in situ hybridization. Ann. Otol. Rhinol. Laryngol. (1995) 104(9 Pt 1):678-684.
89. KUSUKAWA J, SASAGURI Y, MORIMATSU M, KAMEYAMA T: Expression of matrix metalloproteinase-3 in stage I and II squamous cell carcinoma of the oral cavity. J. Oral Maxillofac. Surg. (1995) 53(5):530-534.
90. WESTERLUND A, APAJA-SARKKINEN M, HOYHTYA M, PUISTOLA U, TURPEENNIEMI-HUJANEN T: Gelatinase A-immunoreactive protein in ovarian lesions-prognostic value in epithelial ovarian cancer. Gynecol. Oncol. (1999) 75(1):91-98.
91. GARZETTI GG, CIAVATTINI A, LUCARINI G et al.: Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. AntiCancer Res. (1995) 15(6B):2799-2804.
92. KUNIYASU H, ELLIS LM, EVANS DBet al.: Relative expression of E-cadherin and Type IV collagenase genes predicts disease outcome in patients with respectable pancreatic carcinoma. Clin. Cancer Res. (1999) 5(1):25-33.
93. KOSHIBA T, HOSOTANI R, WADA M et al.: Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer (1998) 82(4):642-650.
94. BARCELLOS-HOFF MH, RAVANI SA: Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. (2000) 60(5):1254-1260.
95. MOINFAR F, MAN YG, ARNOULD L et al.: Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res. (2000) 60(9):2562-2566.
96. KINZLER KW, VOGELSTEIN B: Landscaping the cancer terrain [comment]. Science (1998) 280(5366):1036-1037.
97. WILLENBUCHER RF, AUST DE, CHANG CGetal.:Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am. J. Pathol. (1999) 154(6):1825-1830.
98. MEHINDATE K, AL-DACCAK R, AOUDJIT F et al.: Interleukin-4, transforming growth factor beta 1 and dexamethasone inhibit superantigen-induced prosta-glandin E2-dependent collagenase gene expression through their action on cyclooxygenase-2 and cytosolic phospholipase A2. Lab. Invest. (1996) 75(4):529-538.
99. BUCK TB, YOSHIJI H, HARRIS SR, BUNCE OR, THORGEIRSSON UP: The effects of sustained elevated levels of circulating tissue inhibitor of metalloproteinases-1 on the development of breast cancer in mice. Ann. NY Acad. Sci. (1999) 878:732-735.
100. RUDOLPH-OWEN LA, CANNON P, MATRISIAN LM: Overexpression of the matrix metalloproteinase matrilysin results in premature mammary gland differentiation and male infertility. Mol. Biol. Cell (1998) 9(2):421-435.
101. COUSSENS LM, TINKLE CL, HANAHAN D, WERB Z: Inflammatory cell-derived gelatinase B/MMP-9 regulates proliferation, angiogenesis and malignancy duringsquamous carcinogenesis. Cell(2000) (In Press).
102. MATRISIAN LM: Cancer biology: extracellular proteinases in malignancy. Curr. Biol. (1999) 9(20):R776-778.
103. WITTY JP, WRIGHT JH, MATRISIAN LM: Matrix metallo-proteinases are expressed during ductal and alveolar mammary morphogenesis and misregulation of stromelysin-1 in transgenic mice induces unscheduled alveolar development. Mol. Biol. Cell (1995) 6 (10):1287-1303.
104. HEPPNER-GOSS KJ, BROWN PD, MATRISISAN LM: Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorige-nesis. Int. J. Cancer (1998) 78:629-635.
105. HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumori-genesis. Cell (1996) 86 (3):353-364.
106. BERGERS G, BREKKEN R, MCMAHON J etal: Gelatinase B/MMP-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. (2000) 2:737-744.
107. ITOH T, TANIOKA M, YOSHIDA H et al.: Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. (1998) 58:1048-1051.
108. FANG J, SHING Y, WIEDERSCHAIN D et al.: Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc. Natl. Acad. Sci. USA (2000) 97 (8):3884-3889.
109. YU Q, STAMENKOVIC I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. (2000) 14 (2):163-176.
110. BROOKS PC, SILLETTI S, VON SCHALSCHA TL, FRIEDLANDER M, CHERESH DA: Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell (1998) 92 (3):391-400.
111. O'REILLY MS, HOLMGREN L, SHING Y et al: A novel angiogenesis inhibitor which mediates the suppression of metastasis by a Lewis lung carcinoma. Cell (1994) 79:315-328.
112. DONG Z, KUMAR R, YANG X, FIDLER IJ: Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell (1997) 88 (6):801-810.
113. O'REILLY MS, WIEDERSCHAIN D, STETLER-STEVENSON WG, FOLKMAN J, MOSES MA: Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J. Biol. Chem. (1999) 274 (41):29568-29571.
114. O'REILLY MS, BOEHM T, SHING Y et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 88(2)277-285.
115. STETLER-STEVENSON WG, HEWITT R, CORCORAN M: Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin. Cancer Biol. (1996) 7 (3):147-154.
116. COMPAGNI A, CHRISTOFORI G: Recent advances in research on multistage tumorigenesis. Br. J. Cancer (2000) 83 (1):1-5.
117. PERL AK, WILGENBUS P, DAHL U, SEMB H, CHRISTOFORI G: A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature (1998) 392 (6672):190-193.
118. YONEDA T, SASAKI A, DUNSTAN C etal.: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the biphosphonate ibandronate and tissue inhibitor of the matrix-metalloproteinase-2. J. Clin. Invest. (1997) 99(10):2509-2517.
119. KIM J, YU W, KOVALSKI K, OSSOWSKI L: Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell (1998) 94(3):353-362.
120. KOOP S, KHOKHA R, SCHMIDT EE etal: Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res. (1994) 54(17):4791-4797.
121. MURPHY G, WILLENBROCK F: Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol. (1995) 248:496-510.
122. BODDEN MK, HARBER GJ, BIRKEDAL-HANSEN B etal: Functional domains of human TIMP-1 (tissue inhibitor of metalloproteinases). J. Biol. Chem. (1994) 269 (29):18943-18952.
123. WILLIAMSON RA, CARR MD, FRENKIEL TA, FEENEY J, FREEDMAN RB: Mapping the binding site for matrix metalloproteinase on the N-terminal domain of the tissue inhibitor of metalloproteinases-2 by NMR chemical shift perturbation. Biochemistry (1997) 36 (45):13882-13889.
124. GOMIS-RÜTH FX, MASKOS K, BETZ M etal: Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature (1997) 389 (6646):77-81.
125. MOTT JD, THOMAS CL, ROSENBACH MT et al.: Post-translational proteolytic processing of procollagen C-terminal proteinase enhancer releases a metalloproteinase inhibitor. J. Biol. Chem. (2000) 275 (2):1384-1390.
126. KHOKHA R, WATERHOUSE P, YAGEL S etal: Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science (1989) 243 (4893):947-950.
127. SHOJI A, SAKAMOTO Y, TSUCHIYA T etal: Inhibition of tumor promoter activity toward mouse fibroblasts and their in vitro transformation by tissue inhibitor of metalloproteinases-1 (TIMP-1). Carcinogenesis (1997) 18 (11):2093-2100.
128. KHOKHA R: Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivoby the overexpression of the tissue inhibitor of metalloproteinases-1. J. Natl. Cancer Inst. (1994) 86 (4):299-304.
129. KRÜGER A, FATA JE, KHOKHA R: Altered tumor growth and metastasis of a T-cell lymphoma in TIMP-1 transgenic mice. Blood (1997) 90 (5):1993-2000.
130. CHESLER L, GOLDE DW, BERSCH N, JOHNSON MD: Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood (1995) 86 (12) 4506-4515.
131. DOCHERTY AJ, LYONS A, SMITH BJ etal: Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature (1985) 318 (6041):66-69.
132. BERTAUX B, HORNEBECK W, EISEN AZ, DUBERTRET L: Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J. Invest. Dermatol (1991) 97(4):679-685.
133. YOSHIJI H, HARRIS SR, RASO E et al.: Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int. J. Cancer (1998) 75(1):81-87.
134. GUEDEZ L, COURTEMANCH L, STETLER-STEVENSON M: Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood (1998) 92 (4):1342-1349.
135. GUEDEZ L, STETLER-STEVENSON WG, WOLFF L etal: In vitrosuppression of programmed cell death ofBcells by tissue inhibitor of metalloproteinases-1. J. Clin. Invest (1998) 102 (11):2002-2010.
136. BAKER T, TICKLE S, WASAN H etal: Serum metalloproteinases and their inhibitors: markers for malignant potential. Br. J. Cancer (1994) 70:506-512.
137. KOSSAKOWSKA AE, HUCHCROFT SA, URBANSKI SJ, EDWARDS DR: Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br. J. Cancer (1996) 73 (11):1401-1408.
138. LINDSAY CK, THORGEIRSSON UP, TSUDA H, HIROHASHI S: Expression of tissue inhibitor of metalloproteinase-1 and Type IV collagenase/gelati-nase messenger RNAsin human breast cancer. Human Pathol. (1997) 28(3):359-366.
139. YOSHIJI H, GOMEZ DE, THORGEIRSSON UP: Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer. Int. J. Cancer (1996) 69(2):131-134.
140. ZENG ZS, COHEN AM, ZHANG ZF, STETLER-STEVENSON W, GUILLEM JG: Elevated tissue inhibitor of metallo-proteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin. Cancer Res. (1995) 1(8):899-906.
141. JUNG K, NOWAK L, LEIN M et al.: Matrix metalloprote-inases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/ tissue inhibitor in plasma of patients with prostate cancer. Int. J. Cancer (1997) 74(2):220-223.
142. REE AH, FLORENES VA, BERG JP et al.: High levels of messenger RNAs for tissue inhibitors of metalloprote-inases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin. Cancer Res. (1997) 3(9):1623-1628.
143. MIMORI K, MORI M, SHIRAISHI T et al.: Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br. J. Cancer (1997) 76(4):531-536.
144. MCCARTHY K, MAGUIRE T,MCGREAL Getal.: High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int. J. Cancer (1999) 84(1):44-48.
145. NARUO S, KANAYAMA H, AKI M, KAGAWA S: Gene expressions of Type IV collagenase and tissue inhibitor of metalloproteinases (TIMP) in human bladder cancers. Nippon Hinyokika Gakkai Zasshi (1993) 84(5):841-850.
146. STETLER-STEVENSON WG, BERSCH N, GOLDE DW: Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett. (1992) 296(2):231-234.
147. HAYAKAWA T, YAMASHITA K, OHUCHI E, SHINAGAWA A: Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J. Cell Science (1994) 107(Pt 9)(3):2373-2379.
148. NEMETH JA, RAFE A, STEINER M, GOOLSBY CL: TIMP-2 growth-stimulatory activity: a concentration-and cell type-specific response in the presence of insulin. Exp. Cell Res. (1996) 224(1):110-115.
149. IMREN S, KOHN DB, SHIMADA H, BLAVIER L, DECLERCK YA: Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res. (1996) 56(13):2891-2895.
150. ARII S, MISE M, HARADA T et al.: Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology (1996) 24(2):316-322.
151. STETLER-STEVENSON WG, BROWN PD, ONISTO M, LEVY AT, LIOTTA LA: Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumorcelllines and humantumor tissues. J. Biol. Chem. (1990) 265(23):13933-13938.
152. MOSER PL, HEFLER L, TEMPFER C et al.: Immunohisto-chemical detection of matrix metalloproteinases (MMP) 1 and 2 and tissue inhibitor of metalloprote-inase 2 (TIMP 2) in stage I and II endometrial cancer. AntiCancer Res. (1999) 19(3B):2365-2367.
153. KURAHARA S, SHINOHARA M, IKEBE T et al.: Expression of MMPS, MT-MMP and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck (1999) 21(7):627-638.
154. RING P, JOHANSSON K, HOYHTYA M, RUBIN K, LINDMARK G: Expression oftissue inhibitorof metallo-proteinases TIMP-2 in human colorectal cancer-a predictor of tumour stage. Br. J. Cancer (1997) 76(6):805-811.
155. BEAULIEU E, KACHRA Z, MOUSSEAU N et al.: Matrix metalloproteinases and their inhibitors in human pituitary tumors. Neurosurgery (1999) 45(6):1432-1440; discussion 1440-1431.
156. THOMAS P,KHOKHA R,SHEPHERD FA, FELD R, TSAO MS: Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J. Pathol. (2000) 190(2):150-156.
157. STASKUS PW, MASIARZ FR, PALLANCK LJ, HAWKES SP: The 21-kDa protein is a transformation-sensitive metalloproteinase inhibitor of chicken fibroblasts. J. Biol. Chem. (1991) 266(1):449-454.
158. LU XQ, LEVY M, WEINSTEIN IB, SANTELLA RM: Immuno-logical quantitation of levels of tissue inhibitor of metalloproteinase-1 in human colon cancer. Cancer Res. (1991) 51(23 Pt 1):6231-6235.
159. URÍA JA, FERRANDO AA, VELASCO G, FREIJE JM, LÓPEZ- OTÍN C: Structure and expression in breast tumors of human TIMP-3, a new member of the metalloprote-inase inhibitor family. Cancer Res. (1994) 54(8):2091-2094.
160. BACHMAN KE, HERMAN JG, CORN PG et al.: Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain and other human cancers. Cancer Res. (1999) 59(4):798-802.
161. AMOUR A, SLOCOMBE PM, WEBSTER A et al.: TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. (1998) 435(1):39-44.
162. WANG M, LIU YE, GREENE J et al.: Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene (1997) 14(23):2767-2774.
163. UITTO VJ, FIRTH JD, NIP L, GOLUB LM: Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratino-cytes. Ann. NY Acad. Sci. (1994) 732:140-151.
164. JOHNSON LL, DYER R, HUPE DJ: Matrix metalloprote-inases. Curr. Opin. Chem. Biol. (1998) 2:466-471.
165. DRUMMOND AH, BECKETT P, BROWN PD et al.: Preclinical and clinical studies
166. SHALINSKY DR, BREKKEN J, ZOU H et al.: Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. NY Acad. Sci. (1999) 878:236-270.
167. ADAMS JM, CORY S: Transgenic models of tumor development. Science (1991) 254(5035):1161-1167.
168. HURSTING SD: Experimental models of gene-environment interaction for cancer chemopre-vention studies. Curr. Opin. Oncol. (1997) 9 (5):487-491.
169. BROWN PD: Synthetic inhibitors of matrix metallopro-teinases. In: MatrixMetalloproteinases. Parks WC, Mecham RP (Eds.), Academic Press, San Diego (1998):243-261.
170. BROWN PD, GIAVAZZI R: Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann. Oncol. (1995) 6 (10):967-974.
171. MCCAWLEY LJ, MATRISIAN LM: Matrix metalloprote inases: multifunctional contributors to tumor progres sion. Mol. Med. Today (2000) 6 (4):149-156.
172. SHALINSKY DR, SHETTY B, PITHAVALA Y et al.: Prinomastat: a potent and selective matrix metalloproteinase inhibitor-preclinical and clinical development for oncology. In: Matrix Metalloproteinase Inhibitors in Cancer Therapy. Clendeninn NJ, Appelt K (Eds.), Humana Press, Totowa, New Jersey, USA (2000):143-173.
173. HAQ M, SHAFII A, ZERVOS EE, ROSEMURGY AS: Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer. Cancer Res. (2000) 60 (12):3207-3211.
174. PRONTERA C, MARIANIB, ROSSI C, POGGI A, ROTILIO D: Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int. J. Cancer (1999) 81:761-766.
175. SHALINSKY DR, BREKKEN J, ZOU H et al: Marked antiangiogenic and antitumor efficacy of AG3340in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Clin. Cancer Res. (1999) 5 (7):1905-1907.
176. SHI Z, RAITHATHA S, SPENCER D et al: Enhanced effectiveness of a novel MMP inhibitor, prinomastat (AG3340) with radiation therapy (RT) in aglioma model. Proc. Am. Assoc. CancerRes. (2000) 41:326(A2071).
177. BURKE F, EAST N, UPTON C, PATEL K, BALKWILL FR: Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: enhancement of effect by batimastat. Eur. J. Cancer (1997) 33 (7):1114-1121.
178. GIAVAZZI R, GAROFALO A, FERRI C et al: Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin. Cancer Res. (1998) 4(4):985-992.
179. ZOU H, BREKKEN J, FEELEY R, SHALINSKY DR: Antitumor efficacy and longterm sensitivity to prinomastat (AG3340) after extended in vivo treatment. Clin. Cancer Res. (1999) 5 (Suppl.):52.
180. KLEMENT G, BARUCHEL S, RAK J et al: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. (2000) 105 (8):R15-24.
181. BROWDER T, BUTTERFIELD CE, KRALING BM et al: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. (2000) 60 (7):1878-1886.
182. HANAHAN D, BERGERS G, BERGSLAND E: Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice [comment]. J. Clin. Invest. (2000) 105 (8):1045-1047.
183. KISHI K, MILAS L, HUNTER N, SATO M: Recent studies on anti-angiogenesis in cancer therapy [in process citation]. Nippon Rinsho (2000) 58 (8):1747-1762.
184. BEATTIE GJ, SMYTH JF: Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin. Cancer Res. (1998) 4(8):1899-1902.
185. MALFETANO J, TENG N, BARTER J et al: Marimastat in patients with advanced cancer of the ovary-a dose-finding study. Proc. Am. Soc. Clin. Oncol. (1997) 1331.
186. ZAKNOEN S, WOLFF R, COX J et al: Marimastat in advanced progressive colorectal cancer-a dose-finding study. Proc.Am. Soc. Clin. Oncol. (1997) 968.
187. ROTHENBERG ML, NELSON AR, HANDE KR: New drugs on the horizon: matrix metalloproteinase inhibitors. Stem Cells (1999) 17:237-240.
188. FIELDING J, SCHOLEFIELD R, STUART R et al: Arandom-ized double-blind placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinomas. Proc.Am.Soc. Clin. Oncol. (2000) 929.
189. MALCOLM J, MOORE J, HAMM J et al: A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12-9566 (9566) in patients (PTS) with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (2000) 930.
190. TOLCHER A, ROWINSKY EK, RIZZO J et al: APhase I and pharmacokinetic study of the oral matrix metalloproteinase inhibitor Bay12-9566 in combination with paclitaxel and carboplatin. Proc. Am. Soc. Clin. Oncol. (1999) 617.
191. COLLIER M, SHEPHERD F, AHMANN FR et al.: A novel approach to studying the efficacy of AG3340, a selectiveinhibitorofmatrix metalloproteases (MMPs). Proc. Am. Soc. Clin. Oncol. (1999) 1861.
192. WILDING G, SMALL E, COLLIER M, DIXON M, PITHAVALA Y: A Phase I pharmacokinetic evaluation of matrix metalloprotease (MMP) inhibitor AG3340 in combination with mitoxantrone and prednisone in patients with advanced prostate cancer. Proc. Am. Soc. Clin. Oncol. (1999) 1244.
193. D'OLIMPIO J,HANDE K, COLLIER Met al.: PhaseIstudy of the matrix metalloprotease inhibitor AG3340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (1999) 615.